US ▾
INNV
Earnings call · Jun 2026 (Q4 FY26)

InnovAge Holding Q4 FY26 earnings call INNV

Sep 8, 2026 Source

Executive summary

InnovAge Q4 FY26 — Strong Financial Performance and Strategic Vision for Growth

InnovAge concluded FY26 with exceptional financial performance, marked by significant adjusted EBITDA growth and improved center-level contribution margins, driven by operational efficiencies and census expansion. The company is now entering "InnovAge 3.0," focusing on scaling its value-based care platform through technology, AI, and strategic growth initiatives, while maintaining a disciplined approach to margin management and high-quality care amidst a more tempered rate environment for FY27.

Highlights

5

  • Adjusted EBITDA increased approximately 175% compared with fiscal 2025, reaching $94.6 million for FY26.

  • Center-level contribution margin increased 48.2% to $227.8 million in FY26, representing 23.0% of revenue (up 500 bps YoY).

  • Annual census grew 6.3%, serving approximately 8,230 participants across 20 centers as of June 30, 2026.

  • Reported net income of $9.8 million in Q4 FY26, reversing a net loss of $29.9 million in Q3 FY26.

  • Ended the quarter with a strong balance sheet, including $97.9 million in cash and cash equivalents plus $43.4 million in short-term investments.

Concerns

4

  • Net loss of $0.7 million for FY26, primarily due to a $36.8 million net increase in litigation and settlement expenses.

  • Anticipated fiscal 2027 rate environment is more tempered, with Medicare rate increases of 1.5% to 2.0% and low single-digit Medicaid rate increases.

  • Uncertainty regarding final PACE rate outcomes in California and Colorado, which together represent approximately 70% of the company's census.

  • Corporate general and administrative expenses increased 36.4% to $166.5 million compared to FY25, driven by litigation expenses and higher compensation.

Guidance & targets

CategoryTargetConfidence
Ending Census
8,625 to 8,850 participants
high materiality
High
Member Months
101,000 to 102,500
medium materiality
High
Total Revenue
$1.05 billion to $1.085 billion
high materiality
High
Adjusted EBITDA
$105 million to $115 million
high materiality
High
De Novo Losses
$0.4 million to $0.8 million
medium materiality
High
Medicare Rate Increase
1.5% to 2.0%
high materiality
High
Medicaid Rate Increase
low single-digit
medium materiality
Medium

Risks & headwinds

Litigation and settlement expenses FY26

$36.8 million net increase in FY26

Mitigation:Not explicitly stated, but implies resolution of disputes.

Tempered rate environment FY27

Medicare rate increase of 1.5% to 2.0%; Medicaid low single-digits

Mitigation:Focus on execution, enrollment growth, retention, utilization management, operating efficiency, and leveraging technology/AI.

Uncertainty in final PACE rate outcomes FY27

California and Colorado represent approximately 70% of census

Mitigation:Incorporated responsible assumptions into FY27 outlook based on available information, while recognizing rates are not yet final.

Macroeconomic, geopolitical, and industry-related challenges Ongoing

Not quantified

Mitigation:Not explicitly stated.

What to watch in Q1 FY27

Final PACE rate outcomes in California and Colorado

Next quarter
Current Not yet finalized, responsible assumptions incorporated into FY27 guidance
Target Finalized rates that support the FY27 guidance

Why it matters

These states represent 70% of census, and final rates will significantly impact FY27 revenue and profitability.

California and Colorado are two markets where we have worked with our state partners in the PACE rate-setting processes, which have yet to conclude. We've incorporated what we believe are responsible assumptions into our fiscal 2027 outlook based on the information available to us today, while recognizing that the ultimate rate outcomes are not yet final.

Q&A highlights

How are county-level rates, risk adjustments, and the v28 shift factored into PMPM assumptions for FY27, especially with the 50/50 blend of v22/v28?

Medicare rates are adjusted for the v28 phase-in, moving to a 50/50 blend of v22 and v28 models in FY27 starting January, which provides a boost due to favorable dementia coding. State rates in California and Colorado (70% of census) are still pending finalization, but working assumptions are incorporated. The FY27 rate environment is expected to be manageable, though less robust than FY26.

“This year we're 10% v28, 90% the old model. Next year it's going to be 50/50. And I believe it kicks off in January when it phases in. So we get basically a half a year of the 50/50 phases.”

asked by Benjamin Rossi · answered by Benjamin Adams

2 min read 5 chapters

Detailed narrative

InnovAge 3.0 Strategy and Vision

InnovAge is entering its 'InnovAge 3.0' phase, shifting from platform building (1.0) and strengthening (2.0) to scaling capabilities and capitalizing on market opportunities. The objective is to build a sophisticated value-based care platform to serve more seniors, deliver sustainable performance, and reinvest in the business. This includes growing census within existing footprints, evaluating de novo markets, M&A, joint ventures, and partnerships, and strengthening capabilities as both a payer and provider. The company emphasizes disciplined investment and maintaining non-negotiable standards of quality and compliance.

Leadership and Operational Enhancements

Jim Brown joined as President and COO to bolster operating leadership for the InnovAge 3.0 chapter. His immediate priorities include driving greater consistency across centers, strengthening center-level accountability, improving Epic EMR utilization across interdisciplinary teams, enhancing participant experience, and building robust operating and analytical capabilities. This strategic hire aims to provide greater leadership capacity to support the company's next phase of growth and operational excellence.

Technology and AI Investments for Efficiency and Care

The company is investing in participant experience initiatives like 'Participant 360' and 'voice of the customer,' alongside omni-channel communication technology. Significant focus is on leveraging existing systems (Epic, Oracle, Salesforce) more effectively and integrating AI. AI pilots include an AI-enabled consultation agent for physicians, which reduced external specialist referrals, and a medication optimization agent to identify opportunities for medication and dosing adjustments. AI is also being explored for improving transportation and scheduling efficiency, aiming to enhance care, participant experience, and operational productivity.

Engagement in PACE Policy Discussions

InnovAge notes strong federal interest in the PACE model, with discussions occurring on two parallel tracks. The first involves strengthening the existing PACE program by identifying and removing barriers to growth and adoption, such as enrollment, awareness, and expansion requirements. The second track explores applying PACE's successful capabilities to additional senior populations, particularly Medicare-only adults with functional impairment who are on a trajectory toward institutional care. The company is actively contributing to these dialogues, highlighting PACE's proven ability to deliver strong outcomes and reduce hospitalizations.

FY27 Outlook and Execution Focus

Fiscal 2027 is anticipated to be a year focused on disciplined execution, as the rate environment is expected to be more tempered than FY26. The company's ability to achieve its earnings targets will depend on continued enrollment growth, improved retention, tighter management of utilization and total cost of care, reduction of variation across centers, and leveraging technology and AI for operational efficiency. While rates in key markets like California and Colorado are not yet final, responsible assumptions have been incorporated into the FY27 outlook.

AI-generated summary of the company's earnings call. Not investment advice.